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Abstract The purpose of the present pilot study was to
explore the moderating role of basal inflammation on the
effects of behavioral pain treatment in 41 patients with
long-standing pain. Baseline pro-inflammatory status
moderated behavioral treatment outcomes: higher pre-
treatment levels of Tumor Necrosis Factor (TNF)-a and
Interleukin (IL)-6 were related to less improvement in pain
intensity, psychological inflexibility and in mental health-
related quality of life. The treatment outcomes improved in
the subgroup that had low levels of pro-inflammatory
cytokines at baseline, while the subjects with higher pro-
inflammatory status did not. Altogether, results indicate
that low-grade inflammation may influence the behavioral
treatment outcomes and provide a possible explanation of
the heterogeneity in treatment response.
Keywords Chronic pain  Cognitive behavioral therapy
(CBT)  Psychological inflexibility  Chronic low-grade
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Introduction
Between 20 and 30 % of the adult population in Europe
and in the United States suffer from chronic pain (Breivik
et al. 2006; Johannes et al. 2010). Although significant
advances have been made in the understanding of chronic
pain, a substantial proportion of patients continue to suffer
from detrimental effects due to longstanding pain of
unclear origin. In addition, pharmacological strategies
often fail to reduce symptoms or disability to satisfactory
levels (Goldenberg et al. 2004; Turk 2002), which has
motivated the development of behavioral interventions
aiming at improving self-management of pain. The utility
of interventions based on cognitive behavioral therapy
(CBT) is supported by a large number of studies (Eccleston
et al. 2009; Williams et al. 2012). CBT for pain comprises
a diverse array of interventions targeting maladaptive
cognitive and behavioral strategies to decrease symptoms
and disability. This includes applied relaxation (AR),
which constitutes an empirically supported behavioral
treatment that focuses on specific relaxation strategies to
manage pain (Gustavsson and von Koch 2006; Linton and
Gotestam 1984), and Acceptance and Commitment Ther-
apy (ACT), which promotes acceptance of pain and related
distress, and engagement in personally valued activities
also in the presence of pain (i.e., psychological flexibility)
(Trompetter et al. 2014; Wetherell et al. 2011; Wicksell
et al. 2013; Williams et al. 2012). However, effect sizes are
generally modest and the variability of treatment effects
large. Further developments, such as tailoring treatment, by
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matching interventions with specific subgroups of patients,
may improve outcomes but this requires a better under-
standing of factors that predict or moderate treatment
effects in these types of treatment (Eccleston et al. 2009).
Unfortunately, despite attempts to identify reliable pre-
dictors of treatment effects, characteristics of treatment
responders remain unclear.
One potential factor that could modulate the effect of
behavioral treatment for chronic pain is inflammation.
Alterations in inflammatory processes have been hypothe-
sized as contributor to pain (Watkins and Maier 2005).
During acute activation of the immune system, cytokines
are known to induce a number of behavioral symptoms,
one of which is pain sensitization (Dantzer et al. 2008), and
the cytokine interleukin (IL)-8 has been associated with the
acute development of hyperalgesia in both rodents and
humans (Cunha et al. 1991; Karshikoff et al. 2015). In
addition, low-grade increase in systemic concentrations of
inflammatory markers, including IL-6, IL-8 and tumor
necrosis factor (TNF)-a, have been observed in patients
with chronic pain (Gur and Oktayoglu 2008; Kadetoff et al.
2012; Koch et al. 2007; Parkitny et al. 2013; Wang et al.
2008). In sum, these data suggest that inflammatory status
could contribute to pain. However, to our knowledge, no
study on patients with chronic pain has yet investigated
whether inflammatory status before treatment modulates
the effect of behavioral treatment.
Hence, the aim of the present pilot study was to explore
the influence of inflammatory status on the effects of
behavioral treatment in a sample of adults with chronic
pain, by assessing the moderating effects of baseline (pre-
treatment) inflammation on treatment-induced changes in
pain intensity, pain disability and psychological outcomes
(i.e., psychological inflexibility and health-related quality
of life).
Methods
The design, sample, assessment, treatment content and
effects have been described in detail previously (Kemani
et al. 2015), but a brief description is presented below.
Participants and procedure
Patients were eligible for inclusion if they had longstanding
pain (C6 months), were 18–65 years old, and had a
stable pain medication during the past 2 months. Patients
were excluded if they participated in a concurrent CBT-
based treatment or presented with severe psychiatric co-
morbidity that required immediate assessment and/or
treatment (e.g., high risk of suicide, psychotic symptoms,
and severe depressive episode). The study was approved by
the Regional Ethical Review Board in Stockholm, Sweden
(Permit Number: 2010/662-31/3), and has been performed
in accordance with the ethical standards. Informed consent
was obtained from all individual participants included in
the study. Sixty patients were included in the study, and 49
initiated treatment.
A randomized controlled design was used to evaluate
the effects of the two behavioral treatments (ACT and AR),
and an administrator with no involvement in treatment
delivery conducted the randomization in blocks of 12
(www.random.org). The ACT and AR interventions fol-
lowed written protocols and consisted of 12 weekly group
sessions (90 min). Both interventions were primarily aimed
at improving functioning in the presence of pain. Treat-
ment was delivered by five therapists in the two conditions.
In ACT, the psychologists conducted ten sessions and a
pain physician with formal training in CBT and ACT
conducted two additional sessions (sessions two and eight).
In the AR-condition psychologists conducted all 12 ses-
sions. All therapists were licensed clinical psychologists
with formal training in CBT, ACT and AR.
Blood samples were taken at the pre-treatment assess-
ment and immediately after treatment (last treatment ses-
sion) for all who initiated treatment, except for one who did
not show up for sampling before the initiation of treatment.
Also, blood samples could not be taken at post-treatment
from six other patients (five dropped out from treatment
and one failed to show up for post-treatment sampling). In
total, blood samples were collected from forty-two patients
before and after treatment. One subject who was an outlier
(i.e., value higher than mean +4SD) with respect to con-
centration of TNF-a was excluded. Therefore, forty-one
subjects were included in the study (mean age: 40.9 (range
21–61); 32 women; mean duration of pain: 11 years (range
1–36); type of pain: n = 38 (93 %) idiopathic pain, n = 10
(24 %) fibromyalgia, n = 3 (7 %) neuropathic pain; treat-
ment: n = 18 AR, n = 23 ACT) (Fig. 1).
Medication (pain, psychiatric and anti-inflammatory
drugs) and self-report psychological measurements (pain
intensity, pain disability, psychological inflexibility,
health-related quality of life, and mood state; see ‘‘Self-
report questionnaires’’ section) were assessed in these
patients. One subject did not complete the questionnaire
assessing health-related quality of life before treatment.
Self-report questionnaires
Pain intensity during the past week was assessed using a
numeric rating scale ranging from 0 (‘‘no pain at all’’) to 6
(‘‘extremely painful’’).
Pain disability was assessed using the Pain Disability
Index (PDI), which consists of seven items exploring the
range of disability (from 0 to 10—‘‘no trouble’’ to ‘‘total
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disability’’) that the subject experiences in various daily
activities (Tait et al. 1987). The reliability and validity of
the questionnaire has been analyzed in previous studies,
e.g., by Tait (Tait et al. 1990) reporting a Cronbach’s alpha
of .86.
Psychological inflexibility was measured using the total
score of the Psychological Inflexibility in Pain Scale (PIPS)
(Wicksell et al. 2008). In ACT, psychological flexibility is
defined as the ability to notice and accept interfering
thoughts, emotions and bodily sensations without acting on
them, to facilitate behaving in accordance with personal
values and long-term goals also in the presence of those
negative experiences. The PIPS comprises 12 items, such
as ‘‘I cancel planned activities when I am in pain’’, rated on
a 7-point Likert-scale that ranges from ‘never true’ (1) to
‘always true’ (7). Higher scores indicate greater psycho-
logical inflexibility. Results from two previous studies
illustrate that the questionnaire has adequate statistical
properties (Wicksell et al. 2010).
Health-related quality of life was assessed using a
12-item short version of the Medical Outcomes Study Short
Form (MOS SF)-36 (Ware et al. 1994). Two component
scores are derived from the MOS SF-12 scale, the Physical
Component Score (PCS) and the Mental Component Score
(MCS), which provide measures of physical and mental
well-being, respectively. Luo et al. (2003) have reported
alphas of .77 (PCS) and .80 (MCS), indicating adequate
internal consistency.
Anxiety and depressive symptoms were assessed using
the total score of the Hospital Anxiety and Depression
Scale (HADS) (Zigmond and Snaith 1983). HADS consists
of two subscales measuring anxiety (HADS-a), and
depression (HADS-d) and has 14 items in total, rated on a
4-point Likert-scale. Results from previous studies show
that internal consistency is adequate, .84 for HAD-a and
.82 for HAD-d (Lisspers et al. 1997), and reliably measures
anxiety and depression in hospital settings (Zigmond and
Snaith 1983). Total score of the HADS was used as an
index of subjects’ mood state.
Inflammatory markers
Pre-treatment blood samples were obtained the week prior
to treatment initiation and post-treatment blood samples
were obtained right after the end of the last session (mean
time of blood sample pre-treatment: 11:57; post-treatment:
12:03). Aliquots of serum samples were stored at -80 C
until the assays were performed. Serum concentrations of
the pro-inflammatory markers, IL-6, IL-8 and TNF-a, were
assayed using high-sensitivity enzyme-linked immunosor-
bent assay (ELISA) according to the manufacturer’s
specifications (R&D Systems, Minneapolis, Minnesota).
Sensitivities were 0.039 pg/mL for IL-6, 0.13 pg/mL for
IL-8 and 0.106 pg/mL for TNF-a. Intra- and inter-assay
variability were respectively ±7.4 and ±7.8 % for IL-6,
±5.5 and ±8.5 % for IL-8 and ±5.3 and ±8.4 % for TNF-
a. Concentrations of the three cytokines were log-trans-
formed.
Given that the inflammatory status is probably best
defined by a combination of several cytokine concentra-
tions rather than one cytokine only, composite scores of
inflammation were calculated using a standard method for
identifying latent factors, i.e. Principal Component Anal-
ysis, which has been used in several previous studies (Hsu
et al. 2009; Lasselin et al. 2012; Lasselin et al. 2014). Two
scores were extracted, first using log-transformed IL-6 and
TNF-a pre-treatment concentrations (‘‘composite score
IL-6/TNF-a’’) and then using the three cytokines, IL-6,
TNF-a and IL-8 (‘‘composite score IL-6/TNF-a/IL-8’’).
Statistical analyses
The effect of behavioral treatment on self-reported mea-
sures (pain intensity, pain disability, psychological inflex-
ibility and health-related quality of life) and inflammatory
markers were measured using repeated measures (RM)
ANCOVA, adjusting for age, gender, change in the num-
ber of used medicines (pain, psychiatric and anti-inflam-
matory drugs) and change scores of anxiety and depressive
symptoms (HADS).
The moderating effect of pre-treatment pro-inflamma-
tory status on the behavioral treatment effects was evalu-
ated using the method of Judd, Kenny and McClelland
(2001). According to this method, the change scores
(= [post-assessment—pre-assessment]/pre-assessment) in
pain-related measures were regressed on each pre-treatment
composite score of inflammatory markers, adjusting for age,
Fig. 1 Flow diagram of subjects included in the study
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gender, the changes in the number of used medicines and
change scores of anxiety and depressive symptoms.
The effect of behavioral treatment on self-reported mea-
sures was then assessed in subjects with higher (i.e., com-
posite score in the highest tertile) versus lower (i.e.,
composite score in the lowest tertile) pro-inflammatory
status before treatment, using RM ANCOVA adjusting for
age, gender, change in the number of used medicines and
change scores of anxiety and depressive symptoms. Pairwise
comparisons (Fisher tests) were used as post hoc analyses.
All statistical analyses were performed using SPSS
Statistics 22 (IBM) and a conventional alpha level of 0.05.
Results
Effects of behavioral treatment on self-report
questionnaires and cytokines
The main effect of behavioral treatment (i.e., across con-
ditions) was not significant on any of the self-reported
variables, although tendencies for improvements (p = .07–
.08) were seen for psychological inflexibility and physical
health-related quality of life (Table 1). Behavioral treat-
ment significantly reduced serum TNF-a concentrations
(raw values: from 1.74 ± .67 to 1.65 ± .64 pg/mL, RM
ANCOVA on log values: F(1,36) = 6.29, p = .02,
g2 = .15) but not IL-6 (raw values: from 1.42 ± 1.39 to
1.39 ± 1.30 pg/mL, RM ANCOVA on log values:
F(1,36) = 0.22, p = .88, g2 = .001) or IL-8 concentra-
tions (raw values: from 13.70 ± 6.04 to 12.62 ± 7.24 pg/
mL, RM ANCOVA on log values: F(1,36) = 0.48,
p = .49, g2 = .01).
Moderating effect of baseline inflammation
on treatment outcomes
The moderator analyses of pre-treatment inflammatory
status on the treatment effect (Table 2) revealed that higher
combined concentrations of IL-6 and TNF-a were associ-
ated with lesser improvement in pain intensity following
treatment. In addition, a significant association between
higher composite score of IL-6 and TNF-a concentrations
and lower improvement in psychological inflexibility was
found. Using the composite score of the three cytokines
IL-6, TNF-a and IL-8 reduced these associations. This
suggests that higher levels of both IL-6 and TNF-a before
treatment were associated with lesser improvement in pain
intensity and psychological inflexibility following treat-
ment (Fig. 2a, b). In addition, pre-treatment composite
inflammatory scores were negatively associated with the
changes in mental health-related quality of life (Fig. 2c).
The effect of behavioral treatment was evaluated in
subjects with higher pro-inflammatory status before treat-
ment (i.e., composite score IL-6/TNF-a/IL-8 in the highest
tertile; n = 14, n = 9 ACT, n = 5 AR) versus lower pro-
inflammatory status before treatment (i.e., composite score
IL-6/TNF-a/IL-8 in the lowest tertile; n = 14, n = 10
ACT, n = 4 AR) using RM ANCOVA. A significant
interaction effect between behavioral treatment and pre-
treatment inflammatory status was found for psychological
inflexibility and mental health-related quality of life (re-
spectively, F(1, 22) = 4.6, p = .04, g2 = .17 and
F(1, 22) = 10.4, p = .004, g2 = .32). In particular,
behavioral treatment significantly reduced psychological
inflexibility (Fig. 3a) and improved mental health-related
quality of life (Fig. 3b) only in the group of subjects with
lower pro-inflammatory status at baseline.
Discussion
Results from this pilot study suggest that low-grade
inflammatory state can influence the effects of behavioral
treatment in patients with longstanding pain. In particular,
individuals with higher concentrations of TNF-a and IL-6
before the start of the treatment were more resistant to the
improvement in pain intensity and in psychological vari-
Table 1 Effect of behavioral treatment on pain-related variables
Pain-related variables Pre-treatment Post-treatment F p g2
Pain intensity 4.3 (0.9) 4.0 (1.4) 0.94 .34 .03
Pain disability (PDI) 39.7 (15.1) 34.2 (16.2) 2.34 .14 .06
Psychological inflexibility (PIPS) 56.4 (10.6) 50.7 (16.7) 3.53 .07 .09
Physical health-related QOL (PCS)a 24.5 (11.3) 29.7 (13.4) 3.17 .08 .08
Mental health-related QOL (MCS)a 33.7 (9.6) 33.5 (10.8) 0.002 .96 .000
Data shown as mean (SD) across treatments. Repeated measures ANCOVA were performed with age, gender, the change in number of used
medicines and the relative change scores of HADS as covariates
QOL quality of life, HADS Hospital Anxiety and Depression Scale
a One subject did not complete this scale
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ables contributing to pain (i.e., psychological inflexibility),
as well as in mental health-related quality of life at post-
treatment, than patients with lower level of inflammation.
No substantial overall effect of behavioral treatment on
pain intensity and pain-related variables was found in the
present study. A recent study recently reported that
improvements of behavioral outcomes at post-assessment
were stronger in ACT than in AR therapy (Kemani et al.
2015), which could explain the absence of significant
results when combining the two therapies in the current
study. However, the present study aimed at exploring the
moderating role of inflammation on behavioral treatment
(across conditions). Both therapies were aimed at
improving functioning in the presence of pain, and the
current findings suggest that pre-treatment inflammatory
status may moderate this effect. In particular, results indi-
cate that higher pre-existing levels of IL-6 and TNF-a were
associated with reduced effect of behavioral treatment on
pain intensity, psychological inflexibility as well as mental
health-related quality of life. Additionally, behavioral
treatment was found to have an effect on psychological
inflexibility and mental health-related quality of life in
patients with lower inflammatory status before treatment,
i.e., lower combined concentrations of IL-6, TNF-a and IL-
8, but not in subjects with higher inflammatory status.
Although tentative, the findings from the present study are
potentially relevant as they provide a possible explanation
of the heterogeneity in treatment response that is com-
monly seen in patients suffering from chronic pain. Thus,
the present study suggests that the inflammatory state may
be one of the mechanisms of the persisting behavioral
alterations in patients who do not respond to treatment,
corresponding to previous studies on treatment resistant
depression (Maes et al. 1997; Sluzewska et al. 1997). It
also suggests that patients with higher level of inflam-
mation before starting the treatment may benefit from a
prolonged therapy or the combination with anti-inflam-
matory agents. However, these preliminary results should
be interpreted with caution and the determination of a
precise cut-off associated with non/low response to
treatment is not possible from the present data. In addi-
tion, the range of inflammatory marker concentrations in
patients with chronic pain are usually in the normal range
(in the present study, range of IL-6 raw concentrations:
.18–5.88 pg/mL; TNF-a raw concentrations: .70–3.36 pg/
mL), which implies that inflammatory marker concentra-
tion that predict treatment outcomes are not in the
pathological range. Further studies are warranted to study
and characterize the inflammatory profile that predicts
response/non-response to behavioral treatment for chronic
pain.
The underlying mechanisms of inflammation in pre-
venting behavioral treatment effects may involve the action
of cytokines on the central nervous system (Dantzer et al.
2008). Since most of the effects observed in the present
study were stable in relation to mood state, the mechanisms
underlying this state of resistance are hypothesized to be
independent of an altered inflammation—mood pathway.
However, specific psychological factors may be involved.
For example, it has been shown that non-responders to pain
treatment exhibit poorer coping and higher level of pes-
simism (Litt and Porto 2013). Interestingly, previous
Table 2 Effect of inflammation before treatment on the treatment-induced changes in pain-related variables
Dependent variable Independent variable R2 b p
Pain intensity Composite score IL-6/TNF- a .250 .405 .011
Composite score IL-6/TNF- a/IL-8 .190 .308 .053
Pain disability (PDI) Composite score IL-6/TNF- a .266 .134 .377
Composite score IL-6/TNF- a/IL-8 .268 .138 .353
Psychological inflexibility (PIPS) Composite score IL-6/TNF- a .367 .395 .007
Composite score IL-6/TNF- a/IL-8 .294 .275 .064
Physical health-related QOL (PCS) Composite score IL-6/TNF- a .077 -.054 .754
Composite score IL-6/TNF- a/IL-8 .071 -.010 .952
Mental health-related QOL (MCS) Composite score IL-6/TNF- a .311 2.335 .029
Composite score IL-6/TNF- a/IL-8 .310 2.326 .030
Separate linear regression analyses. Dependent variables are the relative changes from pre- to post-treatment [= (post-treatment - pre-treat-
ment)/pre-treatment)]. Independent variables are pre-treatment composite scores, extracted using principal component analyses, using logarithm-
transformed IL-6 and TNF-a pre-treatment concentrations (composite score IL-6/TNF-a) or the three cytokines, logarithm-transformed IL-6,
TNF-a and IL-8 concentrations (composite score IL-6/TNF-a/IL-8). Regression analyses were adjusted for age, gender, the change in number of
used medicines and the relative change in anxiety and depressive symptoms (HADS). Bold font represents significant values (p\ .05)
TNF-a tumor necrosis factor-a, IL-6 interleukin-6, IL-8 interleukin-8, PDI pain disability, PIPS psychological inflexibility, QOL quality of life,
PCS physical health-related quality of life, MCS mental health-related quality of life, HADS Hospital Anxiety and Depression Scale
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studies have found significant associations of inflammation
with higher levels of pessimism and neuroticism in other
conditions characterized by a chronic low-grade inflam-
matory state, i.e., aging and obesity (Capuron et al. 2011;
Ikeda et al. 2011; Roy et al. 2010). It seems possible that
specific psychological consequences related to a chronic
low-grade inflammatory state could prevent the effect of
treatment by strengthening the use of maladaptive coping
strategies and by reducing the motivational drive.
This study is exploratory in nature and there is a need
for further studies on how inflammation may moderate
improvements in other populations of patients with chronic
pain. The main limitations with the present study were the
relatively low number of subjects, which reduced the sta-
tistical power, and that the number of analyses led to
increased risk for type I-errors. The results should be
interpreted with caution and further studies in larger pop-
ulations are required. Notably, given that some differences
in behavioral outcomes were found after the two types of
treatment (in favor of ACT in comparison to AR) (Kemani
et al. 2015), it would be important to analyze whether the
moderating role of inflammation differs across types of
behavioral treatment. In addition, comparing patients with
and without depression would build on the findings from a
recent study showing significant associations between IL-6
concentrations and pain in patients with depressive symp-
toms, but not in patients without depressive symptoms
(Poleshuck et al. 2013). Finally, because of the restricted
statistical power, we could not assess the confounding or
mediating effect of other factors that may be associated
with pre-treatment inflammatory status and therefore could
explain the observed relationship between pre-treatment
inflammation and treatment outcomes, such as duration of
pain or comorbidities. This will need to be disentangled in
further studies assessing the mechanisms underlying the
effects of inflammation on outcomes of behavioral treat-
ments.
Given that the prevalence of chronic pain is higher in
women compared to men (Mansfield et al. 2015), the
proportion of women was, as expected, high in the present
study (78 %). Although analyses were adjusted for sex,
effects may be inflated by an elevated proportion of
women. Indeed, results from previous studies suggest that
women exhibit higher levels of inflammatory markers and
vulnerability to psychological and mood alterations, which
are more likely related (Derry et al. 2015). The association
of inflammatory status with resistance to behavioral treat-
ment could therefore appear particularly in a female pop-
Fig. 2 Association between
combined concentration of IL-6
and TNF-a before treatment and
the change in pain-related
variables after treatment. Linear
regression analyses, adjusted for
age, gender, the change in
number of used medicines and
the relative change in HADS
scores. Changes in pain-related
variables were calculated as
[= (post-treatment - pre-
treatment)/pre-treatment)]. The
combined concentration of IL-6
and TNF-a was extracted using
principal component analysis
J Behav Med (2016) 39:916–924 921
123
ulation and the effects in men should be specifically
assessed.
A further methodological concern of the present study
was the non-standardized timing of blood sampling, due to
logistic constraints. Several daily assessments during a
number of days, similar to what has been performed in
sleep research (e.g., Lasselin et al. 2015), would be
impractical but may better reflect factual immune alter-
ations associated with chronic pain and would merit further
investigation.
In conclusion, the present study suggests that the pre-
treatment inflammatory state may influence the effects of
behavioral treatment. The results should be seen as pre-
liminary and further studies evaluating the role of inflam-
matory cytokines on the success of behavioral treatment of
chronic pain conditions are warranted .
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